vs
Side-by-side financial comparison of Apollo Commercial Real Estate Finance, Inc. (ARI) and NATURES SUNSHINE PRODUCTS INC (NATR). Click either name above to swap in a different company.
NATURES SUNSHINE PRODUCTS INC is the larger business by last-quarter revenue ($123.8M vs $73.3M, roughly 1.7× Apollo Commercial Real Estate Finance, Inc.). Apollo Commercial Real Estate Finance, Inc. runs the higher net margin — 39.9% vs 3.3%, a 36.5% gap on every dollar of revenue. On growth, NATURES SUNSHINE PRODUCTS INC posted the faster year-over-year revenue change (4.7% vs 4.0%). Over the past eight quarters, NATURES SUNSHINE PRODUCTS INC's revenue compounded faster (5.6% CAGR vs -4.6%).
Apollo Commercial Real Estate Finance, Inc. is a real estate investment trust that originates, acquires and manages commercial real estate debt assets including mortgages, mezzanine loans and mortgage-backed securities, primarily operating in the U.S. market to deliver consistent risk-adjusted returns.
Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.
ARI vs NATR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $73.3M | $123.8M |
| Net Profit | $29.2M | $4.1M |
| Gross Margin | — | 72.5% |
| Operating Margin | 39.7% | 4.3% |
| Net Margin | 39.9% | 3.3% |
| Revenue YoY | 4.0% | 4.7% |
| Net Profit YoY | -28.2% | 1379.4% |
| EPS (diluted) | $0.19 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $73.3M | $123.8M | ||
| Q3 25 | $61.6M | $128.3M | ||
| Q2 25 | $70.9M | $114.8M | ||
| Q1 25 | $65.8M | $113.2M | ||
| Q4 24 | $70.5M | $118.2M | ||
| Q3 24 | $71.6M | $114.6M | ||
| Q2 24 | $81.1M | $110.6M | ||
| Q1 24 | $80.5M | $111.0M |
| Q4 25 | $29.2M | $4.1M | ||
| Q3 25 | $50.8M | $5.3M | ||
| Q2 25 | $20.7M | $5.3M | ||
| Q1 25 | $26.0M | $4.7M | ||
| Q4 24 | $40.7M | $-321.0K | ||
| Q3 24 | $-91.5M | $4.3M | ||
| Q2 24 | $35.8M | $1.3M | ||
| Q1 24 | $-104.5M | $2.3M |
| Q4 25 | — | 72.5% | ||
| Q3 25 | — | 73.3% | ||
| Q2 25 | — | 71.7% | ||
| Q1 25 | — | 72.1% | ||
| Q4 24 | — | 72.0% | ||
| Q3 24 | — | 71.3% | ||
| Q2 24 | — | 71.4% | ||
| Q1 24 | — | 71.2% |
| Q4 25 | 39.7% | 4.3% | ||
| Q3 25 | 82.8% | 7.0% | ||
| Q2 25 | 29.4% | 3.7% | ||
| Q1 25 | 39.7% | 5.4% | ||
| Q4 24 | 57.9% | 3.8% | ||
| Q3 24 | -127.8% | 4.6% | ||
| Q2 24 | 44.2% | 5.1% | ||
| Q1 24 | -129.6% | 4.2% |
| Q4 25 | 39.9% | 3.3% | ||
| Q3 25 | 82.4% | 4.2% | ||
| Q2 25 | 29.3% | 4.6% | ||
| Q1 25 | 39.5% | 4.2% | ||
| Q4 24 | 57.7% | -0.3% | ||
| Q3 24 | -127.9% | 3.8% | ||
| Q2 24 | 44.1% | 1.2% | ||
| Q1 24 | -129.8% | 2.1% |
| Q4 25 | $0.19 | $0.23 | ||
| Q3 25 | $0.34 | $0.30 | ||
| Q2 25 | $0.12 | $0.28 | ||
| Q1 25 | $0.16 | $0.25 | ||
| Q4 24 | $0.25 | $-0.02 | ||
| Q3 24 | $-0.69 | $0.23 | ||
| Q2 24 | $0.23 | $0.07 | ||
| Q1 24 | $-0.76 | $0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $139.8M | $93.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.9B | $161.6M |
| Total Assets | $9.9B | $261.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $139.8M | $93.9M | ||
| Q3 25 | $245.9M | $95.6M | ||
| Q2 25 | $177.6M | $81.3M | ||
| Q1 25 | $166.4M | $86.5M | ||
| Q4 24 | $317.4M | $84.7M | ||
| Q3 24 | $194.3M | $78.7M | ||
| Q2 24 | $174.7M | $68.7M | ||
| Q1 24 | $161.2M | $77.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $2.1M |
| Q4 25 | $1.9B | $161.6M | ||
| Q3 25 | $1.9B | $166.7M | ||
| Q2 25 | $1.8B | $163.7M | ||
| Q1 25 | $1.9B | $167.1M | ||
| Q4 24 | $1.9B | $161.0M | ||
| Q3 24 | $1.9B | $162.6M | ||
| Q2 24 | $2.0B | $156.4M | ||
| Q1 24 | $2.0B | $159.7M |
| Q4 25 | $9.9B | $261.1M | ||
| Q3 25 | $9.5B | $264.8M | ||
| Q2 25 | $9.8B | $254.9M | ||
| Q1 25 | $8.8B | $252.7M | ||
| Q4 24 | $8.4B | $240.9M | ||
| Q3 24 | $9.1B | $245.3M | ||
| Q2 24 | $9.3B | $235.8M | ||
| Q1 24 | $9.2B | $247.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.01× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $142.5M | $9.9M |
| Free Cash FlowOCF − Capex | — | $7.6M |
| FCF MarginFCF / Revenue | — | 6.1% |
| Capex IntensityCapex / Revenue | — | 1.9% |
| Cash ConversionOCF / Net Profit | 4.88× | 2.41× |
| TTM Free Cash FlowTrailing 4 quarters | — | $28.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $142.5M | $9.9M | ||
| Q3 25 | $31.7M | $18.5M | ||
| Q2 25 | $63.2M | $4.3M | ||
| Q1 25 | $39.3M | $2.6M | ||
| Q4 24 | $200.3M | $12.2M | ||
| Q3 24 | $47.2M | $9.6M | ||
| Q2 24 | $50.2M | $1.3M | ||
| Q1 24 | $52.8M | $2.2M |
| Q4 25 | — | $7.6M | ||
| Q3 25 | — | $16.8M | ||
| Q2 25 | — | $3.0M | ||
| Q1 25 | — | $1.5M | ||
| Q4 24 | — | $10.0M | ||
| Q3 24 | — | $7.9M | ||
| Q2 24 | — | $-2.0M | ||
| Q1 24 | — | $-1.5M |
| Q4 25 | — | 6.1% | ||
| Q3 25 | — | 13.1% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | 8.5% | ||
| Q3 24 | — | 6.9% | ||
| Q2 24 | — | -1.9% | ||
| Q1 24 | — | -1.4% |
| Q4 25 | — | 1.9% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | 1.2% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | 3.0% | ||
| Q1 24 | — | 3.3% |
| Q4 25 | 4.88× | 2.41× | ||
| Q3 25 | 0.62× | 3.46× | ||
| Q2 25 | 3.05× | 0.81× | ||
| Q1 25 | 1.51× | 0.55× | ||
| Q4 24 | 4.93× | — | ||
| Q3 24 | — | 2.21× | ||
| Q2 24 | 1.40× | 0.97× | ||
| Q1 24 | — | 0.94× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ARI
Segment breakdown not available.
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
